Ind-Swift Laboratories Limited has informed the Exchange about Conversion

Warrants ConvertedFund Raising View source PDF Explain this filing

INDSWFTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.6%Reaction day

₹142.25

prior close

₹142.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+3.4% vs market

Pharmaceuticals peers, median of 158sector-0.0%+3.6% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 3.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+1.0

15m

+1.5

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.6+0.2+3.4-0.0+3.6

Next day

+5.4+0.4+5.0+0.4+5.0

+3.3-0.6+4.0-0.5+3.9

-3.5-2.8-0.7-2.1-1.4

-10.0-5.4-4.6-3.2-6.9

-3.9-4.4+0.5-1.8-2.1

-1.3-7.1+5.7-4.3+2.9

15d

-0.2-7.8+7.7-5.5+5.3

-4.0-6.6+2.6-6.3+2.2

-5.2+7.7-12.9+3.2-8.5

-6.7+10.3-17.0+7.0-13.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ind-Swift Laboratories has allotted 51,00,000 equity shares (face value ₹10 each) following the conversion of an equal number of Fully Convertible Warrants originally issued on August 30, 2024. The conversion price is ₹121 per share, with the balance subscription amount of ₹46.28 crore received from Essix Biosciences Limited, part of the promoter and promoter group. As a result, the company's paid-up equity share capital has risen to ₹86.71 crore, divided into 8,67,11,558 equity shares. The decision was approved by the Preferential Issue Committee of the Board on February 24, 2026.

Likely market impact

This is a dilution-neutral event for existing shareholders since it completes a previously announced preferential warrant issue to the promoter group, and signals promoter confidence in the company's growth. However, the share count has risen by about 6.2%, which slightly dilutes non-promoter shareholders' stake.